The CEO of Tarsus shares an update on the launch of XDEMVY, and what the company is doing to reach more patients in the quarters ahead

blonca9
Sep 3, 2024
1 min read

Bobby Azamian describes how Tarsus has expanded its salesforce by 50%, and will be adding a DTC element to the launch and derive additional evidence for physicians. Plus, a pipeline update.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

The CEO of Tarsus shares an update on the launch of XDEMVY, and what the company is doing to reach more patients in the quarters ahead

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight